Literature DB >> 27617979

Corrigendum.

.   

Abstract

Year:  2016        PMID： 27617979      PMCID： PMC5027727          DOI： 10.1080/21645515.2016.1229033

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  10 in total

1.  Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.

Authors:  Shalom Ben-Shimol; Noga Givon-Lavi; Eugene Leibovitz; Simon Raiz; David Greenberg; Ron Dagan
Journal:  Clin Infect Dis       Date:  2014-08-25       Impact factor: 9.079

2.  [Streptococcus pneumoniae: serotype distribution, antimicrobial susceptibility, risk factors and mortality in Galicia over a two year-period].

Authors:  Susana Méndez-Lage; Isabel Losada-Castillo; Andrés Agulla-Budiño
Journal:  Enferm Infecc Microbiol Clin       Date:  2015-02-25       Impact factor: 1.731

3.  Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era.

Authors:  Sheldon L Kaplan; Kimberly J Center; William J Barson; Philana Ling-Lin; José R Romero; John S Bradley; Tina Q Tan; Jill A Hoffman; Timothy R Peters; Alejandra Gurtman; Daniel A Scott; James Trammel; William C Gruber; Kristina G Hulten; Edward O Mason
Journal:  Clin Infect Dis       Date:  2015-02-03       Impact factor: 9.079

4.  Decline in antibiotic resistance and changes in the serotype distribution of Streptococcus pneumoniae isolates from children with acute otitis media; a 2001-2011 survey by the French Pneumococcal Network.

Authors:  M Kempf; E Varon; A Lepoutre; A Gravet; R Baraduc; M Brun; H Chardon; J Cremniter; J Croizé; F Dalmay; M-C Demachy; T Fosse; C Grelaud; T Hadou; F Hamdad; J-L Koeck; S Luce; S Mermond; I Patry; A Péchinot; J Raymond; A Ros; C Segonds; B Soullié; D Tandé; M Vergnaud; V Vernet-Garnier; F Wallet; L Gutmann; M-C Ploy; P Lanotte
Journal:  Clin Microbiol Infect       Date:  2014-10-12       Impact factor: 8.067

5.  Trends of pneumococcal meningitis in children after introduction of the 13-valent pneumococcal conjugate vaccine in France.

Authors:  Corinne Levy; Emmanuelle Varon; Capucine Picard; Stéphane Béchet; Alain Martinot; Stéphane Bonacorsi; Robert Cohen
Journal:  Pediatr Infect Dis J       Date:  2014-12       Impact factor: 2.129

6.  Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.

Authors:  Walter H B Demczuk; Irene Martin; Averil Griffith; Brigitte Lefebvre; Allison McGeer; Marguerite Lovgren; Gregory J Tyrrell; Shalini Desai; Lindsey Sherrard; Heather Adam; Matthew Gilmour; George G Zhanel
Journal:  Can J Microbiol       Date:  2013-10-21       Impact factor: 2.419

7.  Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain.

Authors:  Juan Picazo; Jesus Ruiz-Contreras; Juan Casado-Flores; Sagrario Negreira; Maria-Jesus García-de-Miguel; Teresa Hernández-Sampelayo; Enrique Otheo; Cristina Méndez
Journal:  Clin Vaccine Immunol       Date:  2013-08-07

8.  Serotypes and genotypes of invasive Streptococcus pneumoniae before and after PCV10 implementation in southern Brazil.

Authors:  Juliana Caierão; Paulina Hawkins; Fernando Hayashi Sant'anna; Gabriela Rosa da Cunha; Pedro Alves d'Azevedo; Lesley McGee; Cícero Dias
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

9.  Evolution of pneumococcal infections in adult patients during a four-year period after vaccination of a pediatric population with 13-valent pneumococcal conjugate vaccine.

Authors:  Antoni Payeras; Aroa Villoslada; Margarita Garau; Ma Neus Salvador; Ma Carmen Gallegos
Journal:  Int J Infect Dis       Date:  2014-12-23       Impact factor: 3.623

10.  Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England.

Authors:  Catrin E Moore; John Paul; Dona Foster; Saeed A Mahar; David Griffiths; Kyle Knox; Timothy E Peto; A Sarah Walker; Derrick W Crook
Journal:  J Infect Dis       Date:  2014-04-09       Impact factor: 5.226
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.